Header menu link for other important links
X
Immunotoxin therapy for hematologic malignancies: Where are we heading?
Published in Elsevier Ltd
2016
PMID: 26049016
Volume: 21
   
Issue: 2
Pages: 325 - 332
Abstract
The identification of numerous unique targets in recent years has led to the development of various immunotoxins (ITs) for treating hematological malignancies. Some of these ITs have advanced to clinical trials and have resulted in a high response rate against leukemia. Newer targets with improve specificity are also being identified for targeting several leukemias. Currently, several modified versions of ITs with increased efficacy are being constructed and evaluated for cytotoxicity in vitro as well as in vivo. Here, we summarize recent advances in preclinical and clinical studies of recombinant ITs targeting diverse surface receptors. © 2015 Elsevier Ltd. All rights reserved .
About the journal
JournalData powered by TypesetDrug Discovery Today
PublisherData powered by TypesetElsevier Ltd
ISSN13596446
Open AccessNo
Concepts (42)
  •  related image
    CD19 ANTIGEN
  •  related image
    CD20 ANTIGEN
  •  related image
    CD22 ANTIGEN
  •  related image
    CD3 ANTIGEN
  •  related image
    CD30 ANTIGEN
  •  related image
    CD33 ANTIGEN
  •  related image
    CD64 ANTIGEN
  •  related image
    CD7 ANTIGEN
  •  related image
    CD74 ANTIGEN
  •  related image
    FC RECEPTOR
  •  related image
    FC RECEPTOR LIKE 1
  •  related image
    GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR
  •  related image
    IMMUNOTOXIN
  •  related image
    INTERLEUKIN 2 RECEPTOR
  •  related image
    INTERLEUKIN 3 RECEPTOR
  •  related image
    JL 1 PROTEIN
  •  related image
    RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR
  •  related image
    Stem cell factor receptor
  •  related image
    Tumor protein
  •  related image
    Unclassified drug
  •  related image
    IMMUNOTOXIN
  •  related image
    Ligand
  •  related image
    Cytotoxicity
  •  related image
    HEMATOLOGIC MALIGNANCY
  •  related image
    Human
  •  related image
    Immunotherapy
  •  related image
    In vitro study
  •  related image
    In vivo study
  •  related image
    Leukemia
  •  related image
    MULTICENTER STUDY (TOPIC)
  •  related image
    Nonhuman
  •  related image
    PHASE 1 CLINICAL TRIAL (TOPIC)
  •  related image
    PHASE 2 CLINICAL TRIAL (TOPIC)
  •  related image
    PHASE 3 CLINICAL TRIAL (TOPIC)
  •  related image
    Review
  •  related image
    Animal
  •  related image
    HEMATOLOGIC NEOPLASMS
  •  related image
    Animals
  •  related image
    HEMATOLOGIC NEOPLASMS
  •  related image
    Humans
  •  related image
    IMMUNOTOXINS
  •  related image
    Ligands